JPH0482835A - Remedy for dyspigmentation - Google Patents
Remedy for dyspigmentationInfo
- Publication number
- JPH0482835A JPH0482835A JP2198600A JP19860090A JPH0482835A JP H0482835 A JPH0482835 A JP H0482835A JP 2198600 A JP2198600 A JP 2198600A JP 19860090 A JP19860090 A JP 19860090A JP H0482835 A JPH0482835 A JP H0482835A
- Authority
- JP
- Japan
- Prior art keywords
- liquiritin
- remedy
- extract
- dyspigmentation
- pigmentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 claims abstract description 22
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 claims abstract description 22
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 claims abstract description 22
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 claims abstract description 22
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 14
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 16
- 208000000069 hyperpigmentation Diseases 0.000 claims description 9
- 230000003810 hyperpigmentation Effects 0.000 claims description 9
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 230000019612 pigmentation Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000008099 melanin synthesis Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 3
- 206010064127 Solar lentigo Diseases 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 206010024217 lentigo Diseases 0.000 description 12
- 239000008213 purified water Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 206010008570 Chloasma Diseases 0.000 description 9
- 208000003351 Melanosis Diseases 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- -1 anti-inflammatory Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- FRCHKSNAZZFGCA-UHFFFAOYSA-N 1,1-dichloro-1-fluoroethane Chemical compound CC(F)(Cl)Cl FRCHKSNAZZFGCA-UHFFFAOYSA-N 0.000 description 1
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、色素沈着症治療剤に関するものであって、よ
り詳しくは、従来より治療が困難とされている老人性黒
子、日光性黒子、炎症後の色素斑、日焼は等の外界の刺
激に起因しない内因性肝斑等の色素沈着症疾患を副作用
がなく、かつ有効に治療するための薬剤に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a therapeutic agent for hyperpigmentation, and more specifically, it relates to senile lentigines, solar lentigines, and solar lentigines, which have traditionally been difficult to treat. The present invention relates to a drug for effectively treating pigmentation diseases such as post-inflammatory pigment spots and intrinsic melasma that are not caused by external stimuli such as sunburn, without side effects.
内因性肝斑、老人性黒子、日光性黒子、炎症後色素斑治
療剤等の色素沈着症に対する治療法としては、ビタミン
Cの連続内服などによる方法が行われているが、色素沈
着の程度が高度になるとビタミンCの連続内服では改善
されない場合が多い。Continuous oral administration of vitamin C is used to treat pigmentation disorders such as intrinsic melasma, senile lentigines, solar lentigines, and post-inflammatory pigment spots, but the degree of pigmentation In advanced cases, continuous oral administration of vitamin C often does not improve the condition.
また、色素沈着症は表皮内のメラノサイトの量の異常増
大によるもので、これはメラノサイトの数的増加とその
機能昂進に起因する。このメラニンの過剰生成を抑制さ
せ、メラノサイト機能を昂進させる紫外線の影響を防止
する方法として、タルク、亜鉛華、酸化チタン等の粉末
等の光線を散乱させる物質、または紫外線吸収剤、例え
ばパラアミノ安息香酸等を含む軟膏等を用いる方法が行
われていた。Furthermore, hyperpigmentation is caused by an abnormal increase in the amount of melanocytes within the epidermis, and this is caused by an increase in the number of melanocytes and their enhanced function. As a method to suppress the excessive production of melanin and prevent the effects of ultraviolet rays that enhance melanocyte function, substances that scatter light such as powders such as talc, zinc white, and titanium oxide, or ultraviolet absorbers such as para-aminobenzoic acid are used. A method using ointments, etc. containing
また、表皮におけるメラニン生成の抑制作用を持つ物質
、アスコルビン酸、グルタチオン等の脱色剤を含有した
外用剤を用いることも知られている。It is also known to use external preparations containing substances that inhibit melanin production in the epidermis, and depigmenting agents such as ascorbic acid and glutathione.
ところが、これらの外用剤は、主として日光光線により
増大する色素沈着を防止するだめのもので、この外用剤
を単独で使用しても色素沈着症の治療剤としての著しい
効果を期待することはできない。However, these external preparations are mainly intended to prevent pigmentation that increases due to sunlight, and even if these external preparations are used alone, they cannot be expected to have any significant effect as a treatment for pigmentation disorders. .
本出願人は、色素沈着症の治療に有効な薬剤を求めて研
究を続けてきており、コウジ酸を有効成分とするもの(
特願平1−161155号)、胎盤抽出物とコウジ酸ま
たはコウジ酸誘導体との併用(特開昭63−8310号
公報)、サイクロデキストリンとコウジ酸の併用(特開
昭63−8311号公報)、胎盤抽出液とエルゴチオネ
インの併用(特開昭63−8335号公報)、胎盤抽出
液と肝臓抽出液の併用(特公平1−38774号公報)
、哺乳動物、鳥類の肝臓水抽出物を有効成分とするもの
(特開昭618313号公報)が色素沈着症に対する外
用療法に用いられるメラニン生成抑制外用薬剤として有
効であることを明らかにしてきた。The applicant has been conducting research in search of effective drugs for the treatment of hyperpigmentation, and has been researching drugs containing kojic acid as an active ingredient (
Japanese Patent Application No. 1-161155), combination of placenta extract and kojic acid or kojic acid derivative (Japanese Patent Application Laid-open No. 63-8310), combination of cyclodextrin and kojic acid (Japanese Patent Application Laid-Open No. 63-8311) , combination of placenta extract and ergothioneine (JP-A-63-8335), combination of placenta extract and liver extract (JP-A-1-38774)
It has been revealed that a melanin production-suppressing topical melanin production agent containing liver water extracts of mammals and birds as an active ingredient (Japanese Unexamined Patent Publication No. 618313) is effective as a melanin production-inhibiting topical drug used in topical therapy for hyperpigmentation.
本発明者は、これらの発明を追試するとともに、さらに
色素沈着症治療剤として有効な薬剤を求めて研究を続け
る過程において、従来、特開昭64−63506号公報
にみられるように、メラニン生成抑制剤としての効果が
知られているだけにすぎなかったリクイリチンが、その
発症機作の全く異なる前記老人性黒子、日光性黒子、炎
症後の色素斑、日焼は等の外界の刺激に起因しない内因
性肝斑等の色素沈着症疾患を副作用を有することなく、
しかも有効に治療することができるという知見を得、本
発明を完成−するに至った。In the process of further testing these inventions and continuing research in search of a drug that is effective as a pigmentation treatment, the present inventor has discovered that melanin production has Liquiritin, which was only known to have an effect as an inhibitor, has a completely different onset mechanism that is caused by external stimuli such as senile lentigines, solar lentigines, post-inflammatory pigment spots, and sunburn. Does not treat pigmentation diseases such as endogenous melasma without having side effects.
Furthermore, we have found that it can be effectively treated, and have completed the present invention.
すなわち、本発明は、本発明者によって得られた前記新
たな知見をもとに完成されたものであり、それによれば
、リクイリチンを有効成分とする色素沈着症治療剤が提
供される。That is, the present invention was completed based on the above-mentioned new findings obtained by the present inventors, and provides a therapeutic agent for hyperpigmentation that contains liquiritin as an active ingredient.
さらに、本発明によれば、リクイリチンが甘草より低級
アルコールで抽出し、さらに、n−ブタノールで抽出し
た抽出物である色素沈着症治療剤が提供される。Further, according to the present invention, there is provided a pigmentation treatment agent which is an extract obtained by extracting liquiritin from licorice with a lower alcohol and further extracting with n-butanol.
本発明において色素沈着症治療剤として使用されるリク
イリチンは下記構造式を有する化合物である。Liquiritin used as a pigmentation treatment agent in the present invention is a compound having the following structural formula.
H
本化合物は甘草中に含有され、本発明においては甘草抽
出物のリクイリチンを含有する抽出物を外用剤の有効成
分としても良い。H This compound is contained in licorice, and in the present invention, a liquiritin-containing extract of licorice extract may be used as an active ingredient of an external preparation.
本発明の抽出物の原料である甘草はマメ科の薬用植物で
あり、その粉末は古くから去痰、消炎、鎮痙薬として用
いられていた。Licorice, which is the raw material for the extract of the present invention, is a medicinal plant of the Fabaceae family, and its powder has been used as an expectorant, anti-inflammatory, and antispasmodic since ancient times.
また、甘草エキスは経口投与剤として鎮咳、去痰、胃炎
、胃腸機能調整、湿疹等の治療薬として日本薬局方にも
掲載されている。In addition, licorice extract is listed in the Japanese Pharmacopoeia as an orally administered agent for cough suppression, expectoration, gastritis, gastrointestinal function adjustment, and treatment of eczema, etc.
本発明のリクイリチンとしては、甘草の乾燥粉末を水に
浸漬、濾過し、ついでエタノールで抽出した濾液を蒸発
して得られるカンゾウエキス(日本薬局方掲載)を用い
ることができる。好適には、甘草の乾燥粉末を水に浸漬
し、低級アルコール、例えばエタノール、メタノール等
で抽出した抽出物をさらにn−ブタノールで抽出して得
られる抽出液を濾過し、不溶物を分離し、濃縮して得ら
れるリクイリチンの含有量の多い抽出物を用いる。As the liquiritin of the present invention, licorice extract (published in the Japanese Pharmacopoeia) obtained by soaking dry powder of licorice in water, filtering it, extracting it with ethanol, and evaporating the filtrate can be used. Preferably, dry powder of licorice is soaked in water, extracted with a lower alcohol such as ethanol, methanol, etc., the extract is further extracted with n-butanol, and the resulting extract is filtered to separate insoluble matter, An extract with a high content of liquiritin obtained by concentration is used.
本発明の薬剤の対象疾患である皮膚の老化に伴う老人性
黒子、過剰の日光に曝された結果中じる日光性黒子は、
皮膚内に存在するメラノサイト数の増加に伴って症状が
悪化し、最後は癌化することもある疾患であり、炎症後
の色素斑は何らかの皮膚疾患の治癒後に残る黒褐色の色
素斑で難治性の疾患である。Senile lentigines associated with skin aging and solar lentigines caused by excessive exposure to sunlight, which are the target diseases of the drug of the present invention, are
It is a disease in which the symptoms worsen as the number of melanocytes existing in the skin increases, and it may eventually turn into cancer. Post-inflammatory pigment spots are dark brown pigment spots that remain after the healing of some skin disease and are intractable It is a disease.
また、内因性肝斑は、通常の日焼げによる外因性肝斑で
はなく、ホルモン異常、内臓疾患各種治療薬の服用に起
因する内因性の肝斑であり、難治性の色素異常症である
。Intrinsic melasma is not extrinsic melasma caused by normal sunburn, but is intrinsic melasma caused by hormonal abnormalities or the use of various drugs to treat internal diseases, and is an intractable pigmentation disorder. .
本発明の薬剤は、主として経皮投与により患部に適用さ
れるので、その製剤形態は、軟膏剤、液剤、ローション
剤、クリーム、エアゾル剤、パップ剤、プラスター剤等
である。その製剤化は、これらの製剤化に通常使用され
る助剤、添加剤、展着剤等を通常の製剤化方法により経
皮投与剤とする。Since the drug of the present invention is mainly applied to the affected area by transdermal administration, its formulation forms include ointments, solutions, lotions, creams, aerosols, poultices, plasters, and the like. The formulation is made into a transdermal drug using a conventional formulation method using auxiliaries, additives, spreaders, etc. that are commonly used in these formulations.
この経皮投与剤に含有される有効成分であるリクイリチ
ンの含有量は0.01〜20重量%て、好ましくは0.
1〜10重量%である。The content of liquiritin, which is an active ingredient contained in this transdermal preparation, is 0.01 to 20% by weight, preferably 0.01 to 20% by weight.
It is 1 to 10% by weight.
この経皮投与剤を使用する場合は、通常1日2回(朝、
就寝前)に患部に充分塗布する。When using this transdermal drug, usually twice a day (in the morning,
Apply liberally to the affected area (before going to bed).
本発明の有効成分であるリクイリチンの毒性はきわめて
低く、L D50は皮下投与でマウスで2.160mg
/kg、ラットで2,370 mg/kgであり、きわ
めて安全な薬剤である。The toxicity of liquiritin, the active ingredient of the present invention, is extremely low, with an LD50 of 2.160 mg in mice when administered subcutaneously.
/kg, and 2,370 mg/kg in rats, making it an extremely safe drug.
以下、実施例によって本発明の詳細な説明する。 Hereinafter, the present invention will be explained in detail with reference to Examples.
実施例において使用したリクイリチンは次の方法によっ
て得たものである。Liquiritin used in the examples was obtained by the following method.
製造法
甘草50kgを粉砕し、これにエタノール400βを加
えて2時間還流熱抽出を行う。この操作を2回繰り返し
、抽出液を60℃以下で完全に濃縮し、濃縮物15kg
を得る。これを水100βに溶解する。これに飽和含水
η−ブタノール1001を加え、常温て30分よく攪拌
し、静置してブタノール層を分離する。Production method: 50 kg of licorice is ground, ethanol 400β is added thereto, and reflux heat extraction is carried out for 2 hours. Repeat this operation twice to completely concentrate the extract at below 60°C, producing 15 kg of concentrate.
get. This was dissolved in 100β of water. Add saturated hydrated η-butanol 1001 to this, stir well at room temperature for 30 minutes, and leave to stand to separate the butanol layer.
その残留液にさらに同量のn−ブタノールを加え、同操
作を2回繰り返す。3回のn−ブタノール層を合し、水
100βて2回水洗を行い、糖、タンニン等を除去する
。The same amount of n-butanol is further added to the residual liquid, and the same operation is repeated twice. The three n-butanol layers were combined and washed twice with 100β water to remove sugar, tannins, etc.
水洗ブタノール抽出液を合し、60℃以下でブタノール
を溜去する。残留物に3001の水を加え加熱溶解し、
不溶物を濾別する。濾液をさらに50Aまで濃縮し、1
夜放置して上澄液を傾瀉によって分離する。この上澄液
を60℃以下で濃縮し、乾燥フラボノイド画分1 kg
を得る。収率は原料より2%である。The water-washed butanol extracts are combined and the butanol is distilled off at a temperature below 60°C. Add 3001 water to the residue and dissolve by heating.
Insoluble matter is filtered off. The filtrate was further concentrated to 50A and 1
Leave to stand overnight and separate the supernatant by decantation. Concentrate this supernatant at below 60°C to obtain 1 kg of dry flavonoid fraction.
get. The yield is 2% from the raw material.
例1 液剤 (重量%)リクイ
リチン 2.0グリセリン
5.0ソルビトール
4.0ステアリン酸ポリオキシル40 1
.55エタノール 10.0亜
硫酸水素ナトリウム 0.05ウム
0.02
リウム 0.5
〜100
これらを溶解して液剤と
EDTAニナトリ
グルタミン酸ナト
精製水
各成分を混合攪拌し、
する。Example 1 Liquid (weight%) Liquiritin 2.0 Glycerin
5.0 Sorbitol
4.0 Polyoxyl stearate 40 1
.. 55 Ethanol 10.0 Sodium hydrogen sulfite 0.05 Um
0.02 Lium 0.5 to 100 These are dissolved, and the liquid preparation and EDTA nina triglutamate purified water are mixed and stirred.
例2 乳剤性ローション剤
リクイリチン
プロピレングリコール
アスコルビン酸
精製水
大豆レシチン
dl−α−トコフェロール
エタノール
ポリエチレングリコール400
精製水
精製水
EDTAニナトリウム
(重量%)
1.0
0.02
酒石酸水素ナトリウム 02A、B、Cの
各成分を混合攪拌し、これらを溶解して乳剤性ローショ
ン剤とする。Example 2 Emulsion lotion Liquiritin Propylene glycol Ascorbic acid Purified water Soybean lecithin dl-α-Tocopherol Ethanol Polyethylene glycol 400 Purified water Purified water EDTA disodium (% by weight) 1.0 0.02 Sodium hydrogen tartrate 02A, B, The components of C are mixed and stirred to dissolve them to obtain an emulsion lotion.
例3 油脂性軟膏 (重量%)リクイ
リチン 0.1ポリソルベート2
0 5.0デキストラン
0.07エタノール
5.0白色ワセリン 〜100
牛脂 20.0セクノール
2.0dl−α−トコフェロ
ール 0.1モノステアリン酸グリセリン
5、O八を攪拌混合する。Bを加温混合攪拌し、冷
却時に八を混合して油脂性軟膏とする。Example 3 Oily ointment (wt%) Liquiritin 0.1 Polysorbate 2
0 5.0 Dextran
0.07 ethanol
5.0 White Vaseline ~100
Beef tallow 20.0 secnol 2.0 dl-α-tocopherol 0.1 glycerin monostearate
5. Stir and mix O8. Mix and stir B while heating, and when cooled, mix with 8 to obtain an oil-based ointment.
例4 水溶性軟膏
カルボキシビニルポリマー 10プロピレング
リコール 10.0エタノール
8.0ジイソプロパツールアミン
0.15トリアセチン 30
.0キサンクンガム 2.O精製水
3.0亜硫酸水素ナトリ
ウム 0,03精製水
〜100リクイリチン
1.5八を混合し溶解してゲルを製する。ついでB、
CおよびDを順次へに添加して水溶性軟膏とする。Example 4 Water-soluble ointment carboxyvinyl polymer 10 Propylene glycol 10.0 Ethanol
8.0 Diisopropanolamine
0.15 triacetin 30
.. 0 xanthungam 2. O Purified water 3.0 Sodium bisulfite 0.03 Purified water
~100 Liquiritin
1. Mix and dissolve the ingredients to make a gel. Then B,
Add C and D sequentially to make a water-soluble ointment.
例5 乳剤性軟膏 (重量%)白色ワ
セリン 25.0シリコン油
5.0ステアリルアルコール
22.0プロピレングリコール
12,0シヨ糖脂肪酸エステル 5.0ス
テアリン酸ポ
dl−α−トコ
リクイリチン
精製水
各成分を加熱しながら均
乳剤性軟膏とする。Example 5 Emulsion ointment (wt%) White petrolatum 25.0 Silicone oil
5.0 stearyl alcohol
22.0 Propylene glycol
12,0 Sucrose fatty acid ester 5.0 Stearic acid Podl-α-tocoliquiritin Purified water While heating each component, make an emulsion-type ointment.
例6 クリーム
精製水
1.3−ブチレングリコール
ソルビトール
di−PCAナトリウム (50%液)カルボキシビニ
ルポリマー
ポリソルベート60
モノステアリン酸りリセリド
セフノール
ワセリン
ミリスチン酸オクチルドデシル
オクチルドデカノール
リオキン40 2.5
フエロール 015
〜100
に混合し、冷却して
(重量%)
〜100
3.0
7.0
3.0
スクワラン 11.0dl−α−
トコフェロール 0.15精製水
10,0リクイリチン
2.0A、Bを加熱溶解し、Bを八に加えて乳化
し、冷却してクリームとする。別にCを溶解してクリー
ムに添加して製する。Example 6 Cream Purified Water 1.3-Butylene Glycol Sorbitol di-PCA Sodium (50% liquid) Carboxyvinyl Polymer Polysorbate 60 Monostearic Acid Lyceride Cefnol Petrolatum Myristic Acid Octyl Dodecyl Octyl Dodecanol Rioquin 40 2.5 Ferol 015 ~100 and cooled (wt%) ~100 3.0 7.0 3.0 Squalane 11.0dl-α-
Tocopherol 0.15 purified water
10,0 liquiritin
2. Heat and dissolve A and B, add B to 8, emulsify, and cool to make cream. Separately, C is dissolved and added to the cream.
例7 エアゾル剤 (重量%)リクイ
リチン 2.0セタノール
1.2プロピレンクリコール
4.0ステアリン酸 8
.0精製水 〜100フロン
123/141b (57:43) 7.
0各成分を混合溶解してエアゾル用容器に入れ、エアゾ
ル剤とする。Example 7 Aerosol (wt%) Liquiritin 2.0 Cetanol
1.2 Propylene glycol
4.0 Stearic acid 8
.. 0 Purified Water ~100 Freon 123/141b (57:43) 7.
0 Mix and dissolve each component and put it in an aerosol container to make an aerosol.
例8 パップ剤 (重量%)Δ
モノオレイン酸ソルビクン 1.0精製水
〜100ポリアクリル酸ソーダ
70塩化アンモニウム
o3濃グリセリン 200酸化チ
タン 4.0リクイヂン
50A、Bを加温溶解し、BをAに
加えて均一に攪拌し、冷却する。冷却後、塗布剤に塗布
しパップ剤とする。Example 8 Poultice (wt%) Δ Sorbicune monooleate 1.0 Purified water
~100 Sodium polyacrylate 70 Ammonium chloride
o3 concentrated glycerin 200 titanium oxide 4.0 liquidin
50 A and B are dissolved by heating, B is added to A, stirred uniformly, and cooled. After cooling, it is applied to a liniment to make a poultice.
例9 プラスター剤 (重量%)ポリス
チレン−ポリイソプレン−ポリスチレンゴム
36.0流動パラフイン
250エステルガム 15.0ポリ
ブテン 13.0ブチルヒドロキ
ントルエン 1.0ポリアクリル酸
30.0リクイチン
10.0Δを加熱融解し、Bを少しずつ加え均一に攪
拌する。これにCを徐々に加えた後、塗布剤に展延しプ
ラスター剤とする。Example 9 Plastering agent (wt%) polystyrene-polyisoprene-polystyrene rubber
36.0 liquid paraffin
250 Ester gum 15.0 Polybutene 13.0 Butylhydroquine toluene 1.0 Polyacrylic acid
30.0 liquitin
Heat and melt 10.0Δ, add B little by little and stir evenly. After gradually adding C to this mixture, it is spread into a coating agent to form a plaster agent.
次に、本発明の薬剤を用いて内因性肝斑、老人性黒子、
炎症後色素斑の治療効果についての臨床試験結果を示す
。Next, using the drug of the present invention, endogenous melasma, senile lentigo,
The results of a clinical trial regarding the therapeutic effects of post-inflammatory pigment spots are shown.
臨床試験
(1)供試試薬
実施例6のクリーム
〔2)対象患者
大学病院受診患者、内因性肝斑60名、老人性黒子28
名、炎症後色素斑23名。Clinical test (1) Cream of test sample Example 6 [2] Target patients Patients visiting university hospital, 60 patients with intrinsic melasma, 28 senile lentigines
23 people had post-inflammatory pigment spots.
(3)試験方法
1日2回(朝、就寝前)供試試薬を顔面患部の左側に0
.5gずつ充分に塗布し、右側は塗布せずに対照として
試験した。(3) Test method Twice a day (in the morning and before bedtime), apply the test sample to the left side of the affected area of the face.
.. A sufficient amount of 5 g was applied, and the right side was not applied and tested as a control.
(4)判定
塗布後、経時的に左側(処置側)と右側(非処置側)と
を比較して治療状態を目で判定した。(4) Judgment After application, the left side (treated side) and right side (non-treated side) were compared over time to visually judge the treatment status.
判定基準は下記の通りとした。The criteria for evaluation were as follows.
著効;色素斑はほとんど薄れたもの。Excellent effect; most of the pigment spots have faded.
有効;相当に効果ありと判断したもの。Effective; judged to be quite effective.
やや有効:僅かに色素沈着が消退したもの。Slightly effective: Pigmentation has slightly disappeared.
(5)結果 下記第1表の通りてあった。(5) Results It was as shown in Table 1 below.
第 1 表 表中の数字は人数を示す。Chapter 1 Table The numbers in the table indicate the number of people.
本試験での治療期間は早いもので1ケ月、遅くても4ケ
月の処置で効果が現れた。In this study, the treatment period was as early as one month, and the effect was seen after four months at the latest.
本発明によれば、従来より治療が困難であるとされ、し
かもこの疾患の悪化は重大な症状を引き起こすといわれ
ている内因性肝斑、老人性黒子、日光性黒子、炎症後色
素斑等の色素沈着症をきわめて有効に、しかも副作用な
く治癒する薬剤を提供することができる。According to the present invention, treatment of endogenous melasma, senile lentigines, solar lentigines, post-inflammatory pigment spots, etc., which have been considered difficult to treat and whose worsening is said to cause serious symptoms, can be treated. It is possible to provide a drug that cures hyperpigmentation very effectively and without side effects.
Claims (1)
素沈着症治療剤。 2、リクイリチンが甘草より抽出したリクイリチンであ
る請求項1項記載の色素沈着症治療剤。 3、甘草抽出物が甘草を低級アルコールで抽出した後、
さらにn−ブタノールで抽出した抽出物である請求項2
項記載の色素沈着症治療剤。[Scope of Claims] 1. A therapeutic agent for hyperpigmentation, characterized by containing liquiritin as an active ingredient. 2. The agent for treating hyperpigmentation according to claim 1, wherein the liquiritin is liquiritin extracted from licorice. 3. After extracting licorice with lower alcohol,
Claim 2: The extract is further extracted with n-butanol.
The agent for treating hyperpigmentation as described in Section 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP02198600A JP3072768B2 (en) | 1990-07-25 | 1990-07-25 | Pigmentation treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP02198600A JP3072768B2 (en) | 1990-07-25 | 1990-07-25 | Pigmentation treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0482835A true JPH0482835A (en) | 1992-03-16 |
JP3072768B2 JP3072768B2 (en) | 2000-08-07 |
Family
ID=16393894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP02198600A Expired - Fee Related JP3072768B2 (en) | 1990-07-25 | 1990-07-25 | Pigmentation treatment |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3072768B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04117314A (en) * | 1990-09-06 | 1992-04-17 | Kanebo Ltd | Dermal external application composition |
US6248779B1 (en) | 1995-04-21 | 2001-06-19 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
WO2009136611A1 (en) * | 2008-05-09 | 2009-11-12 | 丸善製薬株式会社 | Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutathione, and food, beverage and feed |
JP2009269889A (en) * | 2008-05-09 | 2009-11-19 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink |
JP2011219402A (en) * | 2010-04-08 | 2011-11-04 | Pola Chemical Industries Inc | Pomc production inhibitor |
JP2016222621A (en) * | 2015-06-02 | 2016-12-28 | 学校法人九州文化学園 | Melanin synthesis promoting composition |
-
1990
- 1990-07-25 JP JP02198600A patent/JP3072768B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04117314A (en) * | 1990-09-06 | 1992-04-17 | Kanebo Ltd | Dermal external application composition |
US6248779B1 (en) | 1995-04-21 | 2001-06-19 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
US6306898B1 (en) | 1995-04-21 | 2001-10-23 | Sekisui Kaisha Kogyo Kabushiki Kaisha | External preparations for the treatment of dermatoses |
WO2009136611A1 (en) * | 2008-05-09 | 2009-11-12 | 丸善製薬株式会社 | Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutathione, and food, beverage and feed |
JP2009269890A (en) * | 2008-05-09 | 2009-11-19 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food, drink and feed |
JP2009269889A (en) * | 2008-05-09 | 2009-11-19 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink |
US8828955B2 (en) | 2008-05-09 | 2014-09-09 | Maruzen Pharmaceuticals Co., Ltd. | Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed |
JP2011219402A (en) * | 2010-04-08 | 2011-11-04 | Pola Chemical Industries Inc | Pomc production inhibitor |
JP2016222621A (en) * | 2015-06-02 | 2016-12-28 | 学校法人九州文化学園 | Melanin synthesis promoting composition |
Also Published As
Publication number | Publication date |
---|---|
JP3072768B2 (en) | 2000-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002179516A (en) | Skin-whitening composition | |
KR20030037992A (en) | Composition for skin whitening containing Sitosterol | |
JPH04356424A (en) | Medicated cream and its production | |
KR101142541B1 (en) | Anti-wrinkle cosmetic composition containing oriental herb extract treated by enzyme and its extraction method | |
KR101863297B1 (en) | Composition for preventing or improving skin wrinkle comprising chlorogenic acid and rutin compound as active ingredient | |
KR20100103479A (en) | Cosmetic or dermatological composition containing an orchid extract, and cosmetic care method using said composition | |
JP2549127B2 (en) | Topical drug for suppressing melanin production | |
JP2002179529A (en) | Composition for bleaching | |
JPH04346911A (en) | Cosmetic | |
JPH0482835A (en) | Remedy for dyspigmentation | |
JPH1171231A (en) | Skin whitening agent and skin whitening cosmetic | |
KR100829729B1 (en) | Skin agent composition containing an extract of ophiglossum vulgatum | |
JPH04346917A (en) | Medicated cream and production thereof | |
KR100702329B1 (en) | Compositiion for Inhibiting 5?-Reductase Activity and Cosmetic Composition for Inhibiting Secretion of Sebum containing Extract of Chelidonium majus as Active Ingredient | |
KR20070000675A (en) | Composition containing mung bean extract, bletillae tuber extract and black cohosh extract and use thereof | |
JPH05229931A (en) | Skin-whitening cosmetic | |
KR101017586B1 (en) | Cosmetic composition for skin whitening | |
JP2009203167A (en) | Cytokine production inhibitor and cosmetic composition comprising the same | |
JP2006517180A (en) | A cosmetic composition having a whitening effect, which contains an extract of pursatilla root as a main component | |
JPH07258063A (en) | External preparation for skin | |
CA2018824C (en) | Use of kojic acid for treating pigmentation diseases | |
JP3693213B2 (en) | Anti-aging skin external preparation | |
JPH0672849A (en) | Skin color-lightening cosmetic | |
KR101143432B1 (en) | Cosmetic composition including an extract of Chelidonium Majus L. having skin whitening effect | |
JP2001131079A (en) | Skin preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090602 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100602 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |